Page 12 - Peter Greenleaf News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Operator Greetings, and welcome to the Aurinia Year-end 2020 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is recorded. It's now my pleasure to turn the call over to Glenn Schulman, Senior Vice President, Investor Relations. Please go ahead, sir. Glenn Schulman -- Senior Vice President, Corporate Communications and Investor Relations Thank you, Kevin, and good afternoon, everyone. I'm pleased to welcome you to today's call discussing Aurinia's fourth quarter and year-end financial results. Joining me on the call this afternoon are Peter Greenleaf, ...

Aurinia Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Operational Highlights LUPKYNIS TM is the first FDA-approved oral therapy for lupus nephritis a condition that causes irreversible kidney damage and increases the risk of kidney failure, cardiac events, and death – – Cash, cash equivalents, and investments of $423 million at December 31, 2020 – – Conference call to be hosted today at 4:30 p.m. ET – Aurinia Pharmaceuticals Inc. today issued its financial results for the fourth quarter … – LUPKYNIS TM is the first FDA-approved oral therapy for lup...

Feb 22, 2021 10:00am Beyond clinical and commercial manufacturing, Catalent also had a hand in developing the encapsulation process for Aurinia Pharmaceuticals' drug Lupkynis. (Catalent) Just weeks after Aurinia Pharmaceuticals bagged its first FDA green light, the company is turning to one of its clinical manufacturing partners to help bring its drug to market.  Aurinia enlisted Catalent to deliver commercial supply of its oral lupus nephritis drug Lupkynis (voclosporin), the CDMO said Thursday. The multiyear pact follows Lupkynis' January green light and the companies' successful team-u...

Published: Dec 18, 2020 By Alex Keown Cidara Therapeutics – Christopher Kurtz was named executive vice president of Technical Operations at Cidara Therapeutics. Kurtz brings more than 26 years of experience in global manufacturing, engineering, supply chain, CMC development and program management for drugs and devices at various stages of development. Prior to joining Cidara, Kurtz served as head of commercial API manufacturing at Gilead Sciences. He previously served as vice president, for drug device industrialization at AbbVie, where he led product scale-up and industrialization ...

Aurinia Pharmaceuticals Inc.: Aurinia Announces Collaboration and Licensing Agreement with Otsuka Pharmaceutical Co., Ltd. for the Development and Commercialization of Voclosporin in Europe and Japan - Agreement includes royalties of up to 20 percent on net sales payable to Aurinia - Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH TSX:AUP) ("Aurinia" or the "Company") today announced it has entered into a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of oral voclosporin for the treatment of Lupus Nephritis (LN) in the European Un...